Core Insights - China Guoxin is enhancing its core functions as a state-owned capital operation company, focusing on supporting national strategies through diversified investment tools and financial services [1][6][7] Investment Strategy - Guoxin Fund has invested over 59 billion yuan in strategic emerging industries, achieving full coverage of nine strategic emerging industries and over 220 projects [2][3] - The fund emphasizes early, small, hard, and long-term investments, targeting original technology sources and supporting the development of a modern industrial system [2][3] Capital Deployment - Guoxin Investment has adopted a concentrated investment model, focusing on strategic emerging industries, with over 40 billion yuan allocated to key central enterprises [3][4] - The investment in strategic emerging industries accounts for nearly 80% of Guoxin Investment's total investments, enhancing state capital's control in critical sectors [3] Financial Services - Guoxin Securities has developed a specialized service model for central enterprises, covering 55 enterprises and maintaining a financing scale of over 30% of its total service [5] - The company is actively involved in issuing bonds and supporting green and technology innovation bonds, contributing significantly to the capital market [7] Ecosystem Development - Guoxin is building a "technology-industry-finance" cycle, enhancing the multiplier effect of state capital on the industrial chain [4][6] - The company is innovating in health and data services, developing platforms for drug traceability and digital identity verification [6] Strategic Partnerships - Guoxin Development has invested over 140 billion yuan to support 29 central enterprises, focusing on strategic projects and innovative investment patterns [4] - The company collaborates with local governments to establish funds targeting early-stage hard technology projects [2][4]

Core Viewpoint - The company has approved an associated transaction with China Guoxin, involving a contract worth RMB 2,840,000 for the development of a legal compliance system for equity investment [2][6][21]. Group 1: Meeting and Decision - The 7th meeting of the 12th Board of Directors was held on November 10, 2025, with all 9 directors present, and the meeting complied with legal and regulatory requirements [1][4]. - The proposal regarding the associated transaction with China Guoxin was approved with 5 votes in favor, 0 against, and 0 abstentions, with certain directors abstaining from voting due to conflicts of interest [2][8]. Group 2: Transaction Details - The contract involves the development of the "China Guoxin Equity Investment Legal Compliance Intelligent Review System" by the company's wholly-owned subsidiary, Guoxin Health Service Co., Ltd. [5][17]. - The total contract amount is RMB 2,840,000, which will be paid in installments based on project milestones and acceptance [18][21]. Group 3: Related Party Information - China Guoxin is the actual controller of the company and is classified as a related party under relevant regulations [7][15]. - The cumulative amount of transactions with China Guoxin over the past twelve months has reached RMB 4.434 million, meeting the disclosure standards for board review [23]. Group 4: Independent Directors' Opinion - The independent directors unanimously agreed that the associated transaction aligns with the company's operational needs, is reasonably priced, and does not significantly impact the company's independence or harm the interests of minority shareholders [21][22].

Core Points - Guoxin Health announced the approval of a related party transaction with China Guoxin, involving the construction of a legal compliance intelligent review system for equity investment [2] - The contract amount for the project is RMB 2,840,000, which includes tax [2] - The transaction is classified as a related party transaction since China Guoxin is the actual controller of the company [2]

格隆汇11月10日丨国新健康(000503.SZ)公布，公司全资子公司国新健康保障服务有限公司（简称"国新 健康有限"）与中国国新控股有限责任公司（简称"中国国新"）拟签署《中国国新股权投资法律合规智 能审查系统建设服务合同》，由国新健康有限为中国国新建设"中国国新股权投资法律合规智能审查系 统"，负责完成应用软件的设计开发、移交、培训及相关其他服务工作，合同金额（含税价）为人民币 2,840,000元。 ...

证券简称：国新健康 证券代码：000503 编号：2025-71 中国国新为公司的实际控制人，根据《深圳证券交易所股票上市规则》《公 司章程》及公司《关联交易管理制度》的规定，中国国新为公司的关联方，本次 交易构成关联交易。 （三）事项审议情况 国新健康保障服务集团股份有限公司 关于全资子公司与中国国新关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次关联交易概述 （一）本次关联交易基本情况 国新健康保障服务集团股份有限公司（以下简称"公司"）全资子公司国新 健康保障服务有限公司（以下简称"国新健康有限"）与中国国新控股有限责任 公司（以下简称"中国国新"）拟签署《中国国新股权投资法律合规智能审查系 统建设服务合同》，由国新健康有限为中国国新建设"中国国新股权投资法律合 规智能审查系统"，负责完成应用软件的设计开发、移交、培训及相关其他服务 工作，合同金额（含税价）为人民币 2,840,000 元。 （二）本次交易构成关联交易的说明 含本次关联交易在内，公司连续十二个月内与同一关联人（包含受同一主体 控制或相互存在控制关系的其他关联人）发 ...

证券简称：国新健康 证券代码：000503 编号：2025-70 第十二届董事会第七次会议决议公告 国新健康保障服务集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十二届董事 会第七次会议于2025年11月4日发出会议通知，会议由董事长李永华先生召集并 主持，于2025年11月10日以现场结合通讯方式召开。本次会议应出席董事9人， 实际出席董事9人，公司高级管理人员列席会议。会议的召开符合有关法律、行 政法规、部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了《关于与中国国新关联交易的 议案》。 同意公司全资子公司国新健康保障服务有限公司（以下简称"国新健康有 限"）与中国国新控股有限责任公司（以下简称"中国国新"）签署《中国国 新股权投资法律合规智能审查系统建设服务合同》，由国新健康有限为中国国 新建设"中国国新股权投资法律合规智能审查系统"，合同金额（含税价）为 人民币2,840,000元。 表决情况：5票赞成、0票反对、0票弃权，关联董事李永华、姜开宏、王东 兴、松 ...

Core Viewpoint - Guoxin Health (000503.SZ) announced a contract with China Guoxin Holdings to develop a legal compliance intelligent review system for equity investments, valued at RMB 2,840,000 [1] Group 1 - Guoxin Health's wholly-owned subsidiary, Guoxin Health Guarantee Service Co., Ltd., will undertake the project [1] - The contract includes responsibilities for application software design, development, handover, training, and related services [1] - The total contract amount is RMB 2,840,000, including tax [1]

Group 1 - The core point of the article is that Guoxin Health (SZ 000503) held its 12th seventh board meeting on November 10, 2025, to review proposals including related transactions with China Guoxin [1] - For the first half of 2025, Guoxin Health's revenue composition is 100.0% from the service industry [1] - As of the report date, Guoxin Health has a market capitalization of 9.8 billion yuan [1]

Core Points - Guoxin Health announced the transfer of equity stakes in Guangdong Haihong and Hainan Chemical Fiber through its subsidiaries [2] - The company will transfer 25% and 20% stakes in Guangdong Haihong for a total of RMB 70 million [2] - The transaction has been completed with all payments received and registration changes finalized [2] Summary by Categories Company Actions - Guoxin Health's board and shareholders approved the public transfer of equity stakes in Guangdong Haihong and Hainan Chemical Fiber [2] - The stakes will be transferred through Guoxin Health's subsidiaries, Guoxin Health Guarantee Service Co., Ltd. and Guoxin Yikang Data (Beijing) Co., Ltd. [2] Financial Details - The stakes in Guangdong Haihong are being sold for RMB 38.89 million and RMB 31.11 million respectively [2] - The total transaction amount for the 45% stake in Guangdong Haihong is RMB 70 million [2] Completion Status - As of the announcement date, all transaction payments have been received and the business registration changes have been completed [2]

关于公开挂牌转让广东海虹股权的进展公告 证券简称：国新健康 证券代码：000503 编号：2025-69 国新健康保障服务集团股份有限公司 特此公告。 国新健康保障服务集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 董 事 会 一、交易概述 二零二五年十一月五日 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2023 年 9 月 27 日召开的第十一届董事会第十八次会议和 2023 年 10 月 16 日召开的 2023 年第三 次临时股东大会，审议通过了《关于拟公开挂牌转让海南化纤、广东海虹股权的 议案》。公司将通过公司控股子公司国新健康保障服务有限公司（以下简称"国 新健康有限"）、国新益康数据（北京）有限公司（原名为"益康健康服务有限 公司"，以下简称"国新益康"）分别持有的广东海虹药通电子商务有限公司（以 下简称"广东海虹"）25%、20%股权以公开挂牌方式转让，具体内容详见公司 于 2023 年 9 月 28 日、2023 年 10 月 17 日、2023 年 11 月 3 日和 2024 年 11 月 29 日在《中国证 ...